High-dose furmonertinib for lung cancer after osimertinib stops working
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a higher dose of a targeted therapy called furmonertinib for people with advanced lung cancer that has stopped responding to a previous drug called osimertinib. It may help if you have a certain EGFR mutation and your cancer has grown outside the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced lung adenocarcinoma, a common type of lung cancer.
- You must have had prior treatment with osimertinib, and your cancer must have progressed (grown) outside the brain after that treatment.
- You must have a known EGFR mutation or T790M mutation from prior genetic testing.
- You must have at least one measurable tumor outside the brain as seen on scans.
- You must not have had chemotherapy or immunotherapy before.
- You must not have symptomatic brain metastases, spinal cord compression, or a history of interstitial pneumonia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
This trial tests whether combining an EGFR-targeting drug (furmonertinib) with either ablation or radiation therapy can help patients with early-stage lung cancer who cannot have surgery or choose not to. The goal is to see if this combination approach works better than treatment alone.
This trial tests if a higher dose of furmonertinib can help people with a specific type of lung cancer (NSCLC) that has slowly gotten worse while taking osimertinib. It's for those whose cancer has an EGFR mutation and hasn't spread quickly.
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
This Phase 2 trial studies whether furmonertinib can lower the risk of lung cancer coming back after surgery in certain early-stage lung cancers. You must have EGFR mutations and specific higher-risk features seen on the tumor’s pathology.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.